Related references
Note: Only part of the references are listed.JARID1D Is a Suppressor and Prognostic Marker of Prostate Cancer Invasion and Metastasis
Na Li et al.
CANCER RESEARCH (2016)
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Nicholas D. James et al.
LANCET (2016)
Integrative Clinical Genomics of Advanced Prostate Cancer
Dan Robinson et al.
CELL (2015)
Novel Actions of Next-Generation Taxanes Benefit Advanced Stages of Prostate Cancer
Renee de Leeuw et al.
CLINICAL CANCER RESEARCH (2015)
The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis
Mark M. Pomerantz et al.
NATURE GENETICS (2015)
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Christopher J. Sweeney et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
MDC1 functionally identified as an androgen receptor co-activator participates in suppression of prostate cancer
Chunyu Wang et al.
NUCLEIC ACIDS RESEARCH (2015)
Androgen Receptor Splice Variants Determine Taxane Sensitivity in Prostate Cancer
Maria Thadani-Mulero et al.
CANCER RESEARCH (2014)
ERG induces taxane resistance in castration-resistant prostate cancer
Giuseppe Galletti et al.
NATURE COMMUNICATIONS (2014)
The mutational landscape of lethal castration-resistant prostate cancer
Catherine S. Grasso et al.
NATURE (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
An Integrated Network of Androgen Receptor, Polycomb, and TMPRSS2-ERG Gene Fusions in Prostate Cancer Progression
Jindan Yu et al.
CANCER CELL (2010)
Integrative Genomic Profiling of Human Prostate Cancer
Barry S. Taylor et al.
CANCER CELL (2010)
Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer
Qianben Wang et al.
CELL (2009)
JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer
Yang Xiang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
The X-linked mental retardation gene SMCX/JARID1C defines a family of histone H3 lysine 4 demethylases
Shigeki Iwase et al.
CELL (2007)
Physical and functional association of a trimethyl H3K4 demethylase and Ring6a/MBLR, a polycomb-like protein
Min Gyu Lee et al.
CELL (2007)
Integrative molecular concept modeling of prostate cancer progression
Scott A. Tomlins et al.
NATURE GENETICS (2007)
Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression
S Varambally et al.
CANCER CELL (2005)
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer
SA Tomlins et al.
SCIENCE (2005)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription
E Metzger et al.
NATURE (2005)
Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer
PG Febbo et al.
CLINICAL CANCER RESEARCH (2005)
Timing is everything: Preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer
BJC Eigl et al.
CLINICAL CANCER RESEARCH (2005)
Comparative pharmacokinetics of weekly and every-three-weeks docetaxel
SD Baker et al.
CLINICAL CANCER RESEARCH (2004)
Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy
YP Yu et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance
J Holzbeierlein et al.
AMERICAN JOURNAL OF PATHOLOGY (2004)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
